Sector News

Genmab transfers its ofatumumab collaboration from GSK to Novartis

November 3, 2014
Life sciences
Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and Swiss drug major Novartis to transfer the ofatumumab collaboration, currently with GSK, to Novartis.
 
This follows an announcement in April 2014 that Novartis would acquire GSK’s oncology products, and the transfer of ofatumumab will only become effective on the closing of the GSK/Novartis transaction, expected in the first half of next year.
 
Upon transfer, Novartis is to develop and commercialize ofatumumab in oncology indications and GSK would continue to develop and commercialize the drug for autoimmune indications. The terms of the deal state that Genmab is not required to pay existing funding liabilities, or to fund research and development costs beyond December 31, 2014.
 
Jan van de Winkel, chief executive of Genmab, said: “The collaborations with Novartis and GSK for this innovative therapeutic antibody will help ofatumumab reach its fullest potential, while improving cash flows.”
 
Additionally, on completion of the transfer of the collaboration, Genmab will be able to develop follow-on CD20 products.
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach